Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 28
Filtrar
1.
Intern Med J ; 46(8): 932-41, 2016 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-27185065

RESUMEN

BACKGROUND: Increasingly, patients undergoing non-cardiac surgery are older and have more comorbidities yet preoperative cardiac assessment appears haphazard and unsystematic. We hypothesised that patients at high cardiac risk were not receiving adequate cardiac assessment, and patients with low-cardiac risk were being over-investigated. AIMS: To compare in a representative sample of patients undergoing non-cardiac surgery the use of cardiac investigations in patients at high and low preoperative cardiac risk. METHODS: We examined cardiac assessment patterns prior to elective non-cardiac surgery in a representative sample of patients. Cardiac risk was calculated using the Revised Cardiac Risk Index. RESULTS: Of 671 patients, 589 (88%) were low risk and 82 (12%) were high risk. We found that nearly 14% of low-risk and 45% of high-risk patients had investigations for coronary ischaemia prior to surgery. Vascular surgery had the highest rate of investigation (38%) and thoracic patients the lowest rate (14%). Whilst 78% of high-risk patients had coronary disease, only 46% were on beta-blockers, 49% on aspirin and 77% on statins. For current smokers (17.3% of cohort, n = 98), 60% were advised to quit pre-op. CONCLUSIONS: Practice patterns varied across surgical sub-types with low-risk patients tending to be over-investigated and high-risk patients under-investigated. A more systemised approach to this large group of patients could improve clinical outcomes, and more judicious use of investigations could lower healthcare costs and increase efficiency in managing this cohort.


Asunto(s)
Enfermedad de la Arteria Coronaria/terapia , Procedimientos Quirúrgicos Electivos , Evaluación de Resultado en la Atención de Salud , Cuidados Preoperatorios/métodos , Procedimientos Quirúrgicos Vasculares , Antagonistas Adrenérgicos beta/uso terapéutico , Anciano , Aspirina/uso terapéutico , Australia , Comorbilidad , Quimioterapia , Femenino , Humanos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Masculino , Persona de Mediana Edad , Planificación de Atención al Paciente , Medición de Riesgo , Factores de Riesgo
2.
Med Vet Entomol ; 20(1): 106-14, 2006 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-16608495

RESUMEN

Blowfly larvae (Diptera: Calliphoridae) fulfil an important ecological function in the decomposition of animal remains. They are also used extensively in forensic entomology, predominantly to establish a minimum time since death, or a minimum post-mortem interval, using the larval length as a 'biological clock'. This study examined the larval growth rate of a forensically important fly species, Calliphora vicina Robineau-Desvoidy (Diptera: Calliphoridae) at temperatures of between 4 degrees C and 30 degrees C, under controlled laboratory conditions. The laboratory flies had been trapped initially in London, U.K. The minimum developmental temperature was estimated to be 1 degrees C and 4700 accumulated degree hours (ADH) were required for development from egg hatch to the point of pupariation. Lines fitted to the laboratory larval growth data were found to adequately explain the growth of larvae in the field. The nature of variation in growth rates from geographically isolated populations is discussed.


Asunto(s)
Dípteros/crecimiento & desarrollo , Entomología , Medicina Legal , Temperatura , Animales , Tamaño Corporal/fisiología , Femenino , Larva/crecimiento & desarrollo , Análisis de los Mínimos Cuadrados , Modelos Lineales , Masculino , Factores de Tiempo
4.
Parasitology ; 121 Pt 5: 501-5, 2000 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-11128801

RESUMEN

The vectorial capacity of Biomphalaria pfeifferi from Ndiangue, Senegal, was investigated with an allopatric isolate of Schistosoma mansoni from Nkolbisson, Cameroon. The snail infection rate after exposure to a single miracidium per snail (MD1) was 56. 3 %, and 91.6%, for snails exposed to 5 miracidia per snail (MD5). The minimum pre-patent period was 21 days. The mean total cercarial production for the MDI group was 18,511 cercariae per snail, and 9757 cercariae for the MD5 group. The maximum production of cercariae for 1 day was 4892 observed in a snail from the MDI group at day 43 post-infection. The mean longevity of snails was higher in group MD1 (88 days p.i.) than in group MD5 (65 days p.i.). The chronobiological emergence pattern revealed a circadian rhythm with one shedding peak at mid-day. Comparisons are made with the vectorial capacity of the sympatric combination of B. pfeifferi Senegal/S. mansoni Senegal.


Asunto(s)
Vectores de Enfermedades , Schistosoma mansoni/fisiología , Esquistosomiasis mansoni/transmisión , Caracoles/parasitología , Animales , Camerún , Fenómenos Cronobiológicos/fisiología , Interacciones Huésped-Parásitos , Modelos Lineales , Análisis de Regresión , Schistosoma mansoni/crecimiento & desarrollo , Senegal , Caracoles/fisiología
5.
Genomics ; 57(2): 297-300, 1999 Apr 15.
Artículo en Inglés | MEDLINE | ID: mdl-10198171

RESUMEN

The p21 GTPases, Rho and Cdc42, regulate numerous cellular functions by binding to members of a serine/threonine protein kinase subfamily. These functions include the remodeling of the cell cytoskeleton that is a feature of cell growth and differentiation. Two of these p21 GTPase-regulated kinases, the myotonic dystrophy protein kinase-related Cdc42-binding kinases (MRCKalpha and beta), have been recently characterized in rat. Both of these proteins phosphorylate nonmuscle myosin light chain, a prerequisite for the activation of actin-myosin contractility. Here we report the cDNA cloning of the human homologue of MRCKbeta, CDC42BPB, which was found by Northern blot analysis to be expressed in a wide range of tissues. The human CDC42BPB gene maps to cytogenetic band 14q32.3 by FISH analysis.


Asunto(s)
Cromosomas Humanos Par 14/genética , Proteínas Tirosina Quinasas/genética , Secuencia de Aminoácidos , Northern Blotting , Mapeo Cromosómico , Clonación Molecular , ADN Complementario/química , ADN Complementario/genética , Humanos , Hibridación Fluorescente in Situ , Datos de Secuencia Molecular , Proteína Quinasa de Distrofia Miotónica , ARN Mensajero/genética , ARN Mensajero/metabolismo , Análisis de Secuencia de ADN , Distribución Tisular
7.
Am J Vet Res ; 59(12): 1568-74, 1998 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-9858408

RESUMEN

OBJECTIVE: To evaluate interactions of human intravenous immunoglobulin (IVIG) with canine lymphocytes and monocytes. SAMPLE POPULATION: Heparinized blood samples from 4 clinically normal Beagles. PROCEDURE: Binding ability of IVIG to canine lymphocytes and monocytes was measured by flow cytometry and an indirect immunofluorescent assay. Dual-staining fluorescent assays were done to determine lymphocyte subsets that bind IVIG. Competitive assays were done, using intact canine IgG and Fc fragments, and inhibition of binding was compared with that of F(ab)2 fragments. Ability of IVIG to inhibit phagocytosis of antibody-coated canine RBC also was determined, using a canine mononuclear cell phagocytic assay. RESULTS: IVIG concentrations (10, 1, 0.1, and 0.01 mg/ml) bound to (mean+/-SD) 99.6+/-0.4, 92.4+/-6.1, 20.4+/-24.6 and 2.0+/-5.1 % of canine lymphocytes, respectively, Dual staining analyses with IVIG and canine lymphocyte markers indicated that IVIG bound to CD4, CD8, and B lymphocytes. The aforementioned 4 IVIG concentrations bound to 98.0+/-2.1, 85.5+/-13.5, 64.7+/-32.8, and 26.5+/-17.1 % of monocytes, respectively. Inhibition of IVIG (0.01 mg/ml) binding to monocytes was significant (P< 0.05) in the presence of 1 and 10 mg of canine IgG/ml and 1 mg of canine Fc fragments/ml. In the presence of F(ab')2 fragments of canine IgG, inhibition was not significant, suggesting that binding is Fc mediated. Co-culturing of monocytes, opsonized RBC, and the 4 concentrations of IVIG and no IVIG resulted in 11.8+/-5.1, 27.7+/-12.3, 31.8+15.1, 53.8+/-6.7, and 45 + 12% of the monocytes containing RBC, respectively. Phagocytosis inhibition was significant (P < 0.05) at an IVIG concentration of 10 mg/ml. CONCLUSIONS: IVIG binds to canine lymphocytes and monocytes; binding to the latter is Fc mediated. IVIG also inhibits Fc-mediated phagocytosis of antibody-coated RBC. CLINICAL RELEVANCE: Owing to its ability to inhibit Fc-mediated phagocytosis of antibody-coated RBC, IVIG may be an effective short-term treatment for dogs with immune-mediated hemolytic anemia.


Asunto(s)
Inmunoglobulinas Intravenosas/farmacología , Linfocitos/inmunología , Monocitos/inmunología , Animales , Linfocitos B/inmunología , Sitios de Unión , Linfocitos T CD4-Positivos/inmunología , Linfocitos T CD8-positivos/inmunología , Células Cultivadas , Perros , Eritrocitos/fisiología , Citometría de Flujo , Técnica del Anticuerpo Fluorescente Indirecta , Humanos , Fragmentos Fab de Inmunoglobulinas/inmunología , Fragmentos Fc de Inmunoglobulinas/inmunología , Inmunoglobulina G/inmunología , Inmunoglobulinas Intravenosas/farmacocinética , Fagocitosis
8.
Practitioner ; 242(1585): 243-5, 247, 250 passim, 1998 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-10492980
9.
Growth Factors ; 16(2): 137-51, 1998.
Artículo en Inglés | MEDLINE | ID: mdl-9932231

RESUMEN

We have previously described a non-classical, promoter-specific enhancer for the human Platelet-Derived Growth Factor B (PDGF-B) gene. In JEG-3 choriocarcinoma cells the activity of the enhancer depends upon co-operation with a sequence (the Enhancer-Dependent cis Co-activator "EDC" element) within the promoter. The PDGF-B enhancer fails to activate heterologous promoters, indicating that promoter-specificity depends on an element within the enhancer that can recognise a target sequence within the promoter. Here we identify a sequence within the enhancer of the PDGF-B gene which directs activation of the PDGF-B promoter by distal cis-acting elements. This specifies the wild-type PDGF-B promoter as the target for the enhancer and has been designated the EDC specificity element (EDCse). The cell-type specific nature of this interaction is extended by the observation that the EDCse is also dispensable for enhancer activity in breast-cancer cells (ZR-75). Concomitant to this observation, JEG-3 and ZR-75 cells differ in the binding of nuclear factors to the EDCse. We discuss the relevance of the EDC/EDCse system in regulation of gene expression.


Asunto(s)
Elementos de Facilitación Genéticos , Intrones , Factor de Crecimiento Derivado de Plaquetas/genética , Regiones Promotoras Genéticas , Regiones no Traducidas 5' , Línea Celular , Desoxirribonucleasas de Localización Especificada Tipo II , Humanos , Proteínas Nucleares/metabolismo , Secuencias Reguladoras de Ácidos Nucleicos , Transactivadores/metabolismo , Células Tumorales Cultivadas
10.
J Am Vet Med Assoc ; 209(10): 1730-2, 1996 Nov 15.
Artículo en Inglés | MEDLINE | ID: mdl-8921030

RESUMEN

OBJECTIVE: To validate a new immunoradiometric assay for canine thyroid-stimulating hormone (cTSH) and to document changes in serum cTSH concentration during induction of hypothyroidism in dogs. ANIMALS: Six healthy adult male Beagles. PROCEDURE: Sensitivity, specificity, precision, and accuracy of the cTSH assay were evaluated in vitro. Hypothyroidism was induced in dogs by i.v. administration of sodium iodide I 131 solution. Subsequently, L-thyroxine was administered orally to normalize serum thyroxine concentrations. RESULTS: The cTSH assay appeared to be specific and was sufficiently sensitive to detect cTSH in the serum of these dogs prior to induction of hypothyroidism. There was a 35-fold increase in mean serum cTSH concentration following induction of hypothyroidism, and 35 days after initiation of thyroid replacement therapy, mean serum cTSH concentration was not significantly greater than mean baseline value. CLINICAL IMPLICATIONS: Assay of serum cTSH is likely to prove helpful in the differential diagnosis of primary, secondary, and tertiary hypothyroidism in dogs, and in monitoring response to thyroid hormone replacement treatment.


Asunto(s)
Enfermedades de los Perros/sangre , Perros/sangre , Hipotiroidismo/veterinaria , Tirotropina/sangre , Animales , Diagnóstico Diferencial , Enfermedades de los Perros/diagnóstico , Enfermedades de los Perros/tratamiento farmacológico , Hipotiroidismo/sangre , Hipotiroidismo/diagnóstico , Hipotiroidismo/tratamiento farmacológico , Masculino , Radioinmunoensayo/veterinaria , Valores de Referencia , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Tiroxina/sangre , Tiroxina/uso terapéutico
11.
Hum Mol Genet ; 5 Spec No: 1417-23, 1996.
Artículo en Inglés | MEDLINE | ID: mdl-8875246

RESUMEN

The mutation underlying myotonic dystrophy (DM) was identified at the end of 1991 amidst great rejoicing from the patients supporting the research and, not least, from those who spent so long searching for it. Subsequently, the molecular genetic phenomena associated with DM have been clearly explained by the transmission behaviour of the expanding repeat, which remains the only mutation that has been described in patients. We understand the molecular basis of anticipation, why the severe congenital form is almost exclusively transmitted by affected mothers and we have widely accepted models of the population genetics of DM. Yet, despite all these clearly explained molecular events, we appear to be hardly any closer to understanding the molecular pathology of DM than when the mutation was first identified. To understand the reason for this, we have to look in detail at the mutation itself, and in particular at the locus and its complex nuances. In doing so, we begin to realise that DM is unique amongst the Mendelianly inherited disorders, in that the mutation, because of its location in a very gene-rich region of the genome, probably simultaneously renders several genes dysfunctional. The somatic heterogeneity of the repeat, coupled with the involvement of several genes, accounts for the pleiotropy observed in the phenotype. Added to this complexity is the uncertainty of the level at which gene dysfunction or gain of function is occurring. It is possibly at the level of DNA/chromatin structure and/or RNA regulation/processing, and all of these pathways may, in different tissues, contribute to the final phenotype.


Asunto(s)
Distrofia Miotónica/genética , Animales , ADN , Modelos Animales de Enfermedad , Genes Supresores de Tumor , Genética de Población , Humanos , Familia de Multigenes , Mutagénesis , Distrofia Miotónica/metabolismo , Proteínas Quinasas/genética , ARN , Secuencias Repetitivas de Ácidos Nucleicos
12.
Oncogene ; 11(9): 1873-84, 1995 Nov 02.
Artículo en Inglés | MEDLINE | ID: mdl-7478617

RESUMEN

High-level activity of the human PDGF-B promoter in choriocarcinoma cell lines depends upon an atypical, intronic enhancer-like element which does not function with heterologous promoters tested. An extensive series of mutant PDGF-B promoter-driven constructs identified a sequence flanking the TATA box which is required specifically for enhancer-mediated transcription in human choriocarcinoma cell lines. This element, which we here term an enhancer-dependent cis co-activator (EDC) contains an Inr (initiator) consensus sequence upstream of the TATA box which is required, but not sufficient for its function. Requirement for the EDC is cell type-specific, since it was dispensable for enhancer-mediated transcription in a human breast cancer cell line. Although it lies within the region defined, the TATA box itself is not required for EDC function, or for basal promoter function which may derive from a second Inr-like sequence situated at the transcriptional start site. These observations indicate that interactions between some promoter and enhancer elements may be more complex than that generally described for 'classical' enhancer systems and may suggest an additional function for the initiator motif.


Asunto(s)
Coriocarcinoma/genética , Elementos de Facilitación Genéticos , Factor de Crecimiento Derivado de Plaquetas/genética , Regiones Promotoras Genéticas , Proto-Oncogenes , Secuencias Reguladoras de Ácidos Nucleicos , TATA Box , Neoplasias Uterinas/genética , Secuencia de Bases , Neoplasias de la Mama/genética , Línea Celular , Secuencia de Consenso , Femenino , Humanos , Intrones , Datos de Secuencia Molecular , Mutagénesis Sitio-Dirigida , Plásmidos , Factor de Crecimiento Derivado de Plaquetas/biosíntesis , Embarazo , Proto-Oncogenes Mas , Transcripción Genética , Células Tumorales Cultivadas
13.
J Am Vet Med Assoc ; 207(8): 1055-8, 1995 Oct 15.
Artículo en Inglés | MEDLINE | ID: mdl-7559045

RESUMEN

Seven cats with thyroid carcinomas that had previously undergone surgical removal of neoplastic tissue were treated with 30 mCi of radioactive iodine (131I). Six of the cats had clinical signs of hyperthyroidism; 1 did not. There were no complications associated with 131I treatment, and clinical signs resolved in all cats. Technetium scans of 4 cats made after treatment did not have evidence of isotope uptake. In the remaining 3 cats, small areas of isotope uptake, the intensity of which was equal to or less than the intensity of uptake in the salivary glands, were seen. All 7 cats became hypothyroid after treatment; 4 required L-thyroxine supplementation. One cat was alive 33 months after treatment. The other 6 cats were euthanatized because of unrelated diseases 10 to 41 months after treatment.


Asunto(s)
Adenocarcinoma Folicular/veterinaria , Enfermedades de los Gatos/radioterapia , Radioisótopos de Yodo/uso terapéutico , Neoplasias de la Tiroides/veterinaria , Adenocarcinoma Folicular/diagnóstico por imagen , Adenocarcinoma Folicular/radioterapia , Animales , Enfermedades de los Gatos/diagnóstico por imagen , Enfermedades de los Gatos/etiología , Gatos , Relación Dosis-Respuesta en la Radiación , Femenino , Hipertiroidismo/etiología , Hipertiroidismo/veterinaria , Radioisótopos de Yodo/administración & dosificación , Masculino , Cintigrafía , Radioterapia Adyuvante , Neoplasias de la Tiroides/diagnóstico por imagen , Neoplasias de la Tiroides/radioterapia , Tiroidectomía/veterinaria , Resultado del Tratamiento
14.
J Am Vet Med Assoc ; 207(8): 1066-70, 1995 Oct 15.
Artículo en Inglés | MEDLINE | ID: mdl-7559048

RESUMEN

Outcome of and complications associated with bilateral adrenalectomy in 8 cats with pituitary-dependent hyperadrenocorticism and bilateral adrenocortical hyperplasia and outcome of and complications associated with unilateral adrenalectomy in 2 cats with adrenocortical tumor (adrenocortical adenoma, 1 cat; adrenocortical carcinoma, 1 cat) and unilateral adrenomegaly were determined. Glucocorticoids were administered to all cats at the time of surgery, and mineralocorticoids were administered to the 8 cats that underwent bilateral adrenalectomy. A ventral midline celiotomy was performed in all cats. Intraoperative complications did not develop in any cat. Postoperative complications developed in all cats and included abnormal serum electrolyte concentrations (n = 8), skin lacerations (n = 5), pancreatitis (n = 3), hypoglycemia (n = 2), pneumonia (n = 1), and venous thrombosis (n = 1). Three cats died within 5 weeks after surgery of complications associated with sepsis (n = 2) or thromboembolism (n = 1). Clinical signs and physical abnormalities caused by hyperadrenocorticism resolved in the remaining 7 cats 2 to 4 months after adrenalectomy. Insulin treatment was discontinued in 4 of 6 cats with diabetes mellitus. Median survival time for these 7 cats was 12 months (range, 3 to > 30 months). Two cats died of acute adrenocortical insufficiency 3 and 6 months after bilateral adrenalectomy, 2 cats were euthanatized because of chronic renal failure 3 and 12 months after bilateral (n = 1) or unilateral (n = 1) adrenalectomy, and 2 cats were alive 9 and 14 months after bilateral adrenalectomy. In the remaining cat, clinical signs recurred 10 months after the cat had undergone unilateral adrenalectomy.(ABSTRACT TRUNCATED AT 250 WORDS)


Asunto(s)
Adrenalectomía/veterinaria , Hiperfunción de las Glándulas Suprarrenales/veterinaria , Enfermedades de los Gatos/cirugía , Hiperfunción de las Glándulas Suprarrenales/diagnóstico , Hiperfunción de las Glándulas Suprarrenales/mortalidad , Hiperfunción de las Glándulas Suprarrenales/cirugía , Animales , Enfermedades de los Gatos/diagnóstico , Enfermedades de los Gatos/mortalidad , Gatos , Quimioterapia Adyuvante/veterinaria , Femenino , Estudios de Seguimiento , Masculino , Complicaciones Posoperatorias/veterinaria , Estudios Retrospectivos , Análisis de Supervivencia , Resultado del Tratamiento
16.
Parasitology ; 102 Pt 2: 237-41, 1991 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-1852491

RESUMEN

During 1988 and 1989, the mesenteric veins of 901 cattle were examined for the presence of schistosomes at the Kandy slaughterhouse (Sri Lanka). The overall prevalence of infection was 31.2%. Animals younger than 2 years were less infected (21.3%) than those older than 5 years (47.9%). Based on the number of paired worms counted, three intensities of infection were recognized: low (1-20 pairs), moderate (21-100 pairs) and heavy (greater than 100 pairs). Intensities increased with the age of the animals but remained low (average 10 worm pairs). The worm burden increased by approximately 20% for each step in age group. The number of miracidia/100 g faeces was measured in 85 animals of all age groups and intensities of infection; 77% of the samples contained less than 100 miracidia. Miracidia counts decreased with age; moderately and heavily infected animals in each age group had the highest and the lowest counts, respectively. This may be due to a host immune response. The results raise questions on the sensitivity of faecal egg counts as a diagnostic method for visceral schistosomiasis in cattle.


Asunto(s)
Enfermedades de los Bovinos/epidemiología , Schistosoma/crecimiento & desarrollo , Esquistosomiasis/veterinaria , Mataderos , Factores de Edad , Animales , Bovinos , Heces/parasitología , Recuento de Huevos de Parásitos/veterinaria , Distribución de Poisson , Prevalencia , Esquistosomiasis/epidemiología , Sri Lanka/epidemiología
17.
J Vet Pharmacol Ther ; 14(1): 90-5, 1991 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-2038099

RESUMEN

Reduction of the prolonged terminal elimination phase of gentamicin may be caused by diabetes mellitus, irrespective of the model of diabetes. To test this hypothesis, five normal dogs, three dogs with alloxan-induced diabetes mellitus, and four dogs with naturally occurring diabetes mellitus (all of which were given exogenous insulin to control hyperglycemia) were given 4.4 mg/kg gentamicin intravenously. Serum pharmacokinetics were analyzed using non-compartmental pharmacokinetics assuming a sum of exponential terms. Gentamicin pharmacokinetics during the first 8 h were the same in normal and diabetic dogs. Over 7 days, MRT in normal dogs (5830 +/- 2970 min, mean +/- SD) was longer (P less than 0.01) than in diabetic dogs (136 +/- 164 min). In diabetic dogs, Cls was greater (3.01 +/- 0.86 ml/min/kg) than in normal dogs (1.45 +/- 0.11 ml/min/kg; P less than 0.01), whereas Vd(ss) was smaller in diabetic dogs (0.405 +/- 0.508 l/kg) than in normal dogs (8.56 +/- 4.48 l/kg; P less than 0.01). Serum gentamicin concentrations were less than 0.020 microgram/ml by 2 days in all of the diabetic dogs, but were 0.048 +/- 0.018 microgram/ml at 7 days in normal dogs. Thus, diabetes mellitus, either induced by alloxan administration or naturally occurring, abolished the terminal elimination phase of gentamicin disposition in a non-rodent species.


Asunto(s)
Diabetes Mellitus Experimental/metabolismo , Enfermedades de los Perros/metabolismo , Gentamicinas/farmacocinética , Animales , Perros , Gentamicinas/administración & dosificación , Inyecciones Intravenosas/veterinaria , Tasa de Depuración Metabólica , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA